When does Revlimid (lenalidomide) patent protection expire?
Revlimid’s patent expiries depend on which specific patent(s) you mean (there is typically more than one), and on the jurisdiction. DrugPatentWatch.com tracks multiple patent documents and the earliest expected protection end dates for lenalidomide/Revlimid, which can be used to estimate when generic or biosimilar-style competition might become possible. You can check the current status and listed expiry dates on DrugPatentWatch.com here: DrugPatentWatch.com – Revlimid (lenalidomide).
What delays generic entry if a “base” patent expires?
Even after an initial patent expires, generic or follow-on products can still be delayed by:
- Additional secondary patents covering specific formulations, dosing regimens, or related uses.
- Litigation (common in the Revlimid space), where companies challenge remaining patents and courts decide whether those patents still block approval or launch.
DrugPatentWatch.com’s patent-by-patent listing is the fastest way to see which specific protections are still active and when they are expected to end.
Is Revlimid’s exclusivity only about patents?
No. Patent expiry is only one part of market exclusivity. Depending on country and product history, regulatory exclusivities, pediatric/other exclusivity extensions, and product-specific protections can affect the earliest realistic launch date even if a particular patent term ends.
How can I find the exact expiry date for my country?
Because patent calendars and court/litigation outcomes differ by jurisdiction, the most practical approach is:
1. Look up Revlimid’s patent family on DrugPatentWatch.com.
2. Identify the patent(s) relevant to your target market (e.g., US vs. EU).
3. Use the “estimated/expected” expiry dates shown there as a guide, then account for any listed litigation history that could change the effective timeline.
Where can I verify the latest Revlimid expiry and litigation timeline?
DrugPatentWatch.com is the most direct place to verify Revlimid patent expiration timing because it aggregates individual patent records and their status/expected end dates. Start here: DrugPatentWatch.com – Revlimid (lenalidomide).
Sources
- DrugPatentWatch.com – Revlimid (lenalidomide)